DuPont Nutrition & Health Science earns probiotic health claim in Brazil

DuPont Nutrition & Health has received approval from the Brazilian Health Regulatory Agency (ANVISA) recognizing a health claim for the Bifidobacterium lactis HN019 probiotic strain. The approval means foods and supplements containing the strain can now include the claim “Bifidobacterium lactis HN019 may contribute to gastrointestinal health” on product packaging.

“During its careful evaluation process, the health authority has recognized the potential health effect of HN019 and our expertise as a reliable probiotic supplier. For our customers, it means the approval process for their products is more likely to be swift and successful,” said Carolina Zago, regulatory affairs South America, DuPont Nutrition & Health.

Numerous in vitro and clinical studies have documented the positive effect of HN019 on gastrointestinal health and immune function. In two dietary intervention studies, consumption of HN019 was seen to modulate the composition of gut microbiota favorably—even at a low dose. A meta-analysis of four clinical trials also has shown that daily consumption of HN019 enhances cellular immune activity in healthy elderly adults.